Theralase Technologies Inc told investors it had filed a US patent for its dosimetry fibre optic cage (DFOC) technology ahead of a Phase Ib clinical study.
The DFOC technology means the firm can remotely control the laser delivered to organs, such as the bladder, when undergoing treatment with the firm's lead anti-cancer drug TLD-1433.
This drug is currently under investigation for the destruction of non-muscle invasive bladder cancer (NMIBC) and work in the clinical study involves installing a water based solution of TLD-1433 via catheter into the bladder of a patient before, under general anaesthetic, inserting a rigid cystoscope into the urethra.
Once in the bladder, the DFOC is deployed (like an umbrella) to strategically place optical detectors at 12 predetermined locations in the bladder to monitor and remotely control the amount of laser light delivered, providing a uniform distribution of laser light.
Theralase chief executive and president Roger Dumoulin-White said this latest invention was focused on precisely controlling the amount of laser light received by the bladder wall and "should increase the safety, tolerability and efficacy of the TLD-1433 treatments in the destruction of bladder cancer".
The news comes after on Monday, Theralase revealed it had been granted a US patent for its lead anti-cancer drug, TLD-1433, by the United States Patent and Trademark Office (USPTO).
It provides patent protection for tens of thousands of metal based photodynamic compounds (PDCs); including, Theralase's TLD-1433, currently under investigation by the company for the destruction of non-muscle invasive bladder cancer (NMIBC).
The US patent provides patent protection for Theralase's second major platform of anti-cancer PDCs for 20 years from date of filing, plus an allowable extension of 433 days, providing a minimum patent protection in the US of TLD-1433 and tens of thousands of more compounds until June 22, 2034.